These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
628 related articles for article (PubMed ID: 19060632)
1. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632 [TBL] [Abstract][Full Text] [Related]
2. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890 [TBL] [Abstract][Full Text] [Related]
3. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Breynaert C; Ferrante M; Fidder H; Van Steen K; Noman M; Ballet V; Vermeire S; Rutgeerts P; Van Assche G Am J Gastroenterol; 2011 Apr; 106(4):778-85. PubMed ID: 21407184 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab]. Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078 [TBL] [Abstract][Full Text] [Related]
5. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
7. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Wee JS; Petrof G; Jackson K; Barker JN; Smith CH Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545 [TBL] [Abstract][Full Text] [Related]
8. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356 [TBL] [Abstract][Full Text] [Related]
9. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888 [TBL] [Abstract][Full Text] [Related]
10. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Kugathasan S; Levy MB; Saeian K; Vasilopoulos S; Kim JP; Prajapati D; Emmons J; Martinez A; Kelly KJ; Binion DG Am J Gastroenterol; 2002 Jun; 97(6):1408-14. PubMed ID: 12094858 [TBL] [Abstract][Full Text] [Related]
11. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026 [TBL] [Abstract][Full Text] [Related]
12. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253 [TBL] [Abstract][Full Text] [Related]
13. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Seiderer J; Göke B; Ochsenkühn T Digestion; 2004; 70(1):3-9. PubMed ID: 15297773 [TBL] [Abstract][Full Text] [Related]
14. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683 [TBL] [Abstract][Full Text] [Related]
15. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P; Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441 [TBL] [Abstract][Full Text] [Related]
17. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368 [TBL] [Abstract][Full Text] [Related]
18. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Maser EA; Villela R; Silverberg MS; Greenberg GR Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170 [TBL] [Abstract][Full Text] [Related]
19. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373 [TBL] [Abstract][Full Text] [Related]
20. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]